Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY (DISCOVERY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04916210|
Recruitment Status : Recruiting
First Posted : June 7, 2021
Last Update Posted : June 7, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke" is defined as either (1) an acute ischemic stroke (AIS, or blood clot in the brain), (2) an intracerebral hemorrhage (ICH, or bleeding in the brain), (3) or an aneurysmal subarachnoid hemorrhage (aSAH, or bleeding around the brain caused by an abnormal bulge in a blood vessel that bursts).
The investigators hypothesize that:
- The size, type and location of the stroke play an important role in recovery of thinking and memory abilities after stroke, and pre-existing indicators of brain health further determine the extent of this recovery.
- Specific stroke events occurring in individuals with underlying genetic or biological risk factors can cause further declines in brain heath, leading to changes in thinking and memory abilities after stroke.
- Studying thinking and memory alongside brain imaging and blood samples in patients who have had a stroke allows for earlier identification of declining brain health and development of individualized treatment plans to improve patient outcomes in the future.
|Condition or disease|
|Ischemic Stroke Intracerebral Hemorrhage Subarachnoid Hemorrhage Dementia, Vascular Mild Cognitive Impairment Vascular Cognitive Impairment|
This is a prospective, multi-center, observational, nested-cohort study. A total of 8,000 patients hospitalized at the DISCOVERY clinical sites with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled.
All participants will undergo baseline screening for evidence of pre-stroke dementia. Those who pass baseline screening will complete a blood draw and a series of cognitive and functional assessments at baseline.
Participants will undergo in-person (3-6 months, 18 months) and telephone (annual) follow-up visits for the duration of the study to assess for longitudinal cognitive and functional outcomes. In addition to Tier 1 procedures, at each in-person follow-up visit, Tier 2 participants will also undergo brain MRI scanning, comprehensive cognitive assessment batteries and longitudinal blood collection; and Tier 3 participants will also complete a specialized imaging of the brain (amyloid- and tau-PET/CT scans), which is intended to identify special biomarkers of dementia.
|Study Type :||Observational|
|Estimated Enrollment :||8000 participants|
|Official Title:||Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY|
|Actual Study Start Date :||March 5, 2021|
|Estimated Primary Completion Date :||November 30, 2025|
|Estimated Study Completion Date :||November 30, 2025|
- Change in post-stroke cognitive impairment and dementia (PSCID) diagnosis status [ Time Frame: Baseline to 48 months post-index stroke ]
- Change in cognitive function [ Time Frame: Baseline to 3-6, 12, 18, 24, 36 and 48 months post-index stroke ]
Biospecimen Retention: Samples With DNA
A blood sample will be collected from all participants at baseline for genomic and blood-based biomarker analyses. Tier 2 and 3 participants will undergo additional blood draws at each in-person follow-up visit for the collection of whole blood and RNA for longitudinal blood-based biomarker and DNA methylation (DNAm) analyses.
Plasma, whole blood and RNA samples will be frozen and stored at the DISCOVERY Biorepository at the University of California, San Diego (UCSD) for further processing, storage and analysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Age ≥18 years
- Admitted to the hospital with a diagnosis of acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), or aneurysmal subarachnoid hemorrhage (aSAH)
- Radiographic confirmatory evidence of: (1) AIS (based on a focal area of restricted diffusion on MRI), (2) non-traumatic ICH (based on evidence of acute parenchymal hemorrhage CT or brain MRI) or (3) non-traumatic acute aSAH (based on evidence of subarachnoid hemorrhage on CT or MRI and evidence of aneurysm on CT angiography, MR angiography, or conventional catheter-based angiography)
- Able to complete baseline visit in person or by phone within 6 weeks of stroke onset
- Able to provide informed consent by self or proxy
- Fluent in English or Spanish prior to stroke onset
- Documented history of pre-stroke dementia or fails dementia pre-screen
- Concurrently enrolled into a study that is not approved under the DISCOVERY Co-Enrollment Policy
Unable to complete study protocol (advanced directives such as comfort measures only, or inability to complete the study due to severe medical/behavioral co-morbidities), as determined by physician investigator during screening process
Additional exclusion criteria for Tier 2 participants:
Contraindication to MRI: presence of electrically, magnetically, or mechanically activated implants (such as cardiac pacemakers, cochlear implants, implanted pumps); or metallic clips in the brain
Additional exclusion criteria for Tier 3 participants:
- Age <50 years
- Women who are pregnant or seeking to become pregnant
- Known to have one of the following genetic conditions which can increase the risk of developing cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, Down's syndrome.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04916210
|Contact: James Meschia, MD||904-953-6515|
|United States, Colorado|
|University of Colorado||Recruiting|
|Denver, Colorado, United States, 80045|
|Contact: Karen Orjuela, MD, MS|
|Principal Investigator: Karen Orjuela, MD, MS|
|United States, Florida|
|Jacksonville, Florida, United States, 32224|
|Contact: Michelle Lin, MD, MPH|
|Principal Investigator: Michelle Lin, MD, MPH|
|United States, Illinois|
|The University of Chicago Medical Center||Recruiting|
|Chicago, Illinois, United States, 60637|
|Contact: Elisheva Coleman, MD|
|Principal Investigator: Elisheva Coleman, MD|
|United States, Iowa|
|University of Iowa||Recruiting|
|Iowa City, Iowa, United States, 52242|
|Contact: Enrique Leira, MD, MS|
|Principal Investigator: Enrique Leira, MD, MS|
|United States, Maryland|
|University of Maryland Medical Center||Recruiting|
|Baltimore, Maryland, United States, 21201|
|Contact: Prachi Mehndiratta, MBBS|
|Contact: Gunjan Parikh, MD|
|Principal Investigator: Prachi Mehndiratta, MBBS|
|Principal Investigator: Gunjan Parikh, MD|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Mark Etherton, MD, PhD|
|Principal Investigator: Mark Etherton, MD, PhD|
|United States, North Carolina|
|Wake Forest Baptist Health||Recruiting|
|Winston-Salem, North Carolina, United States, 27157|
|Contact: Cheryl Bushnell, MD|
|Principal Investigator: Cheryl Bushnell, MD|
|Principal Investigator:||Natalia Rost, MD, MPH||Massachusetts General Hospital|
|Principal Investigator:||Steven Greenberg, MD, PhD||Massachusetts General Hospital|
|Responsible Party:||Natalia Rost, MD, Professor of Neurology, Massachusetts General Hospital|
|Other Study ID Numbers:||
U19NS115388 ( U.S. NIH Grant/Contract )
|First Posted:||June 7, 2021 Key Record Dates|
|Last Update Posted:||June 7, 2021|
|Last Verified:||June 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
Contingent upon approval from the DISCOVERY Project Steering Committee and Sharing Subcommittee, or the NINDS (upon completion of the study), data, imaging and/or samples from consenting participants may be shared with other external researchers for future research. All identifiers and study-specific codes will be removed and assigned a second randomized identifier. The key linking each identifier to a study-specific code will be in the possession of the DISCOVERY Repository Core and will not be shared with external researchers.
Upon completion of the study, the study database will be available to NINDS along with a data dictionary and all information needed to utilize the data in future research in accordance with the informed consent. De-identified genetic information derived from this study will be deposited in the US NIH genomic database (dbGAP and future iterations) and used for future research.
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Central Nervous System Diseases
Nervous System Diseases
Intracranial Arterial Diseases
Arterial Occlusive Diseases